Ann: Half Yearly Report and Accounts, page-3

The message cannot be any clearer, am I missing something here?

"“In anticipation of a positive CE Mark decision, we also began laying the foundations to support commercialisation activities in the EU. This included meetings with key hospitals across the region, enhanced logistical arrangements in preparation for commercial shipment and development of a promotional campaign for Health Care Professionals to be commenced post CE Mark approval.”

“Noting that all clinical, technical and statistically concerns previously raised by the Clinical Oversight Committee have been closed out since October 2019, we remain confident of a positive CE Mark approval for the OncoSil™ device. We will update the market on developments on this front.”